Abstract:Abstract: The tumor suppressor protein p53, a transcription factor playing a key role in cancer prevention, interacts with DNA as its primary means of determining cell fate in the event of DNA damage. When it becomes mutated, it opens damaged cells to the possibility of reproducing unchecked, which can lead to formation of cancerous tumors. Despite its critical role, therapies at the molecular level to restore p53 native function remain elusive, due to its complex nature. Nevertheless, considerable information has been amassed, and new means of investigating the problem have become available. Objectives: We consider structural, biophysical, and bioinformatic insights and their implications for the role of direct and indirect readout and how they contribute to binding site recognition, particularly those of low consensus. We then pivot to consider advances in computational approaches to drug discovery. Materials and methods: We have conducted a review of recent literature pertinent to the p53 protein. Results: Considerable literature corroborates the idea that p53 is a complex allosteric protein that discriminates its binding sites not only via consensus sequence through direct H-bond contacts, but also a complex combination of factors involving the flexibility of the binding site. New computational methods have emerged capable of capturing such information, which can then be utilized as input to machine learning algorithms towards the goal of more intelligent and efficient de novo allosteric drug design. Conclusions: Recent improvements in machine learning coupled with graph theory and sector analysis hold promise for advances to more intelligently design allosteric effectors that may be able to restore native p53-DNA binding activity to mutant proteins. Clinical relevance: The ideas brought to light by this review constitute a significant advance that can be applied to ongoing biophysical studies of drugs for p53, paving the way for the continued development of new methodologies for allosteric drugs. Our discoveries hold promise to provide molecular therapeutics which restore p53 native activity, thereby offering new insights for cancer therapies. Graphical abstract: Structural representation of the p53 DBD (PDBID 1TUP). DNA consensus sequence is shown in gray, and the protein is shown in blue. Red beads indicate hotspot residue mutations, green beads represent DNA interacting residues, and yellow beads represent both.

A transcriptionally active DNA-binding site for human p53 protein complexes

Δ113p53/Δ133p53 Converts P53 from a Repressor to a Promoter of DNA Double-Stand Break Repair.

Arginine Methylation of Hnrnp K Enhances P53 Transcriptional Activity.

p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60.

A Global Map of P53 Transcription-Factor Binding Sites in the Human Genome.

The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription

p53 rapidly restructures 3D chromatin organization to trigger a transcriptional response

Acetylation of P53 Augments Its Site-Specific DNA Binding Both in Vitro and in Vivo.

Recognition of the disordered p53 transactivation domain by the transcriptional adapter zinc finger domains of CREB-binding protein

Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53

Determinants of p53 DNA binding, gene regulation, and cell fate decisions

Tumor Suppressor P53 Can Participate in Transcriptional Induction of the GADD45 Promoter in the Absence of Direct DNA Binding

Full-atomistic Molecular Dynamics Analysis of p53 Active Tetramer

p53motifDB: integration of genomic information and tumor suppressor p53 binding motifs

Structure of the p53/RNA polymerase II assembly

A Novel Mechanism for P53 to Regulate Its Target Gene ECK in Signaling Apoptosis

Navigating the complexity of p53-DNA binding: implications for cancer therapy

Structural Basis for Reactivating the Mutant TERT Promoter by Cooperative Binding of P52 and ETS1.

A Conserved Mechanism for Binding of p53 DNA-Binding Domain and Anti-Apoptotic Bcl-2 Family Proteins

Transactivation by partial function P53 family mutants is increased by the presence of G-quadruplexes at a promoter site

Deciphering the acetylation code of p53 in transcription regulation and tumor suppression